Cardiooncology: current status of the issue, interdisciplinary interaction

Cover Page

Cite item

Full Text

Abstract

Current methos of treatment of oncological pathology significantly increase survival rates and patients’ lifespan. However, treatment of malignant tumors leads to development of adverse reactions decreasing its effectiveness and negatively affecting quality of life and survival. It was shown that short- and long-term cardiovascular complications significantly affect the results of therapy.

The article presents data on current scientific research in cardio-oncology touching on the problems of cardiotoxicity, concomitant cardiological disorders in oncological patients, cardiac rehabilitation, and patients’ quality of life. The importance of multidisciplinary approach in the context of reducing the risk of cardiovascular complications is demonstrated.

About the authors

D. D. Tsyrenov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: d.tsyrenov@ronc.ru
ORCID iD: 0000-0002-1723-0780

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

E. B. Tsyrenova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-4853-308X

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

S. Yu. Sysoev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-3703-6296

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

References

  1. Clark R.A., Marin T.S., Berry N.M. et al. Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment. Cardiooncology 2017;3(6):1–10. doi: 10.1186/s40959-017-0025-7
  2. Eschenhagen T., Force T., Ewer M.S. et al. Cardiovascular side effects of cancer therapies: a position statement from the heart failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13(1):1–10. doi: 10.1093/eurjhf/hfq213
  3. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015;12(9):547–58. doi: 10.1038/nrcardio.2015.65
  4. Schoormans D., Pedersen S.S., Dalton S. et al. Cardiovascular co-morbidity in cancer patients: the role of psychological distress. Cardiooncology 2016;2(1):9. doi: 10.1186/s40959-016-0019-x
  5. Mehta L.S., Watson K.E., Barac A. et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 2018;137(8):30–66. doi: 10.1161/CIR.0000000000000556
  6. Jones L.W., Haykowsky M.J., Swartz J.J. et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435–41. doi: 10.1016/j.jacc.2007.06.037
  7. Howlader N., Ries L.A.G., Mariotto A.B. et al. Improved estimates of cancer-specific survival rates from population-based. J Natl Cancer Inst 2010;102(20):1584–98. doi: 10.1093/jnci/djq366
  8. Bowles E.J., Wellman R., Feigelson H.S. et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012;104(17):1293–305. doi: 10.1093/jnci/djs317
  9. Curigliano G., Cardinale D., Dent S. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016;66(4):309–25. doi: 10.3322/caac.21341
  10. Swain M.S., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97(11):2869–79. doi: 10.1002/cncr.11407
  11. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015;12(9):547–58. doi: 10.1038/nrcardio.2015.65
  12. Stein-Merlob A.F., Rothberg M.V., Ribas A., Yang E.H. Cardiotoxicities of novel cancer immunotherapies. Heart 2021;107(21):1694–703. doi: 10.1136/heartjnl-2020-318083
  13. Edwards B.K., Noone A.M., Mariotto A.B. et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120(9):1290–314. doi: 10.1002/cncr.28509
  14. Lloyd-Williams M., Friedman T. Depression in palliative care patients – a prospective study. Eur J Cancer Care (Engl) 2001;10(4):270–4. doi: 10.1046/j.1365-2354.2001.00290.x
  15. Henriksson M.M., Isometsä E.T., Hietanen P.S. et al. Mental disorders in cancer suicides. J Affect Disord 1995:36(1–2):11–20. doi: 10.1016/0165-0327(95)00047-x
  16. Bodurka-Bevers D., Basen-Engquist K., Carmack C.L. et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78(3, Pt. 1):302–8. doi: 10.1006/gyno.2000.5908
  17. Hamer M., Molloy G.J., Stamatakis E. Psychological distress as a risk factor for cardiovascular events: pathophysiological and behavioral mechanisms. J Am Coll Cardiol 2008;52(25):2156–62. doi: 10.1016/j.jacc.2008.08.057
  18. Stephen A.S., Rebecca F., Martin J.S. et al. Psychological distress as a risk factor for coronary heart disease in the Whitehall II. Int J Epidemiol 2002;31(1):248–55. doi: 10.1093/ije/31.1.248
  19. Søgaard M., Thomsen R.W., Bossen K.S. et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013;5(Suppl. 1):3–29. doi: 10.2147/CLEP.S47150
  20. Zamorano J.L., Lancellotti P., Muñoz D.R. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 2016;19(1):9–42. doi: 10.1002/ejhf.654
  21. Koroukian S.M., Murray P., Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 2006;24(15):2304–10. doi: 10.1200/JCO.2005.03.1567
  22. Lee L., Cheung W.Y., Atkinson E., Krzyzanowska M.K. Impact of comorbidity on chemotherapy use and outcomes in solid tumours: a systematic review. J Clin Oncol 29(1):106–17. doi: 10.1200/JCO.2010.31.3049
  23. Bellizzi K.M., Rowland J.H. The role of comorbidity, symptoms and age in the health of older survivors following treatment for cancer. Future Med Aging Health 2007;3(5):625–35. doi: 10.2217/1745509X.3.5.625
  24. Sarfati D., Koczwara B., Jackson C. The impact of comorbidity on cancer and its treatments. CA Cancer J Clin 2016;66(4):337–50. doi: 10.3322/caac.21342
  25. Piccirillo J.F., Feinstein A.R. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996;77(5):834–42. doi: 10.1002/(SICI)1097- 0142(19960301)77:53.0.CO;2-E
  26. Monica I., Rama V., Deepa J. et al. Impact of comorbidities on quality of life in breast cancer patients. Ind J Cardiovasc Dis Women WINCARS 2016;1(4):25–8. doi: 10.1055/s-0038-1656491
  27. Friedland C.J. Head and neck cancer: identifying depression as a comorbidity among patients. Clin J Oncol Nurs 2019;23(1):99–102. doi: 10.1188/19.CJON.99-102
  28. Shen Q., Anna Jöud A., Schelin M.E.C. et al. Psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer: a population-based cohort study in Skåne, Sweden. Breast Cancer Res 2019;21(1):139. doi: 10.1186/s13058-019-1232-y
  29. Laukkanen J.A., Kunutsor S.K. Cardiac rehabilitation improves prognosis among patients with co-existing cancer and cardiovascular diseases. Int J Cardiol 2021;15;345:109–10. doi: 10.1016/j.ijcard.2021.10.143
  30. Williamson T., Moran C., Chirico D. et al. Cancer and cardiovascular disease: the impact of cardiac rehabilitation and cardiorespiratory fitness on survival. Int J Cardiol 2021;343:139–45. doi: 10.1016/j.ijcard.2021.09.004
  31. Lahousse A., Roose E., Leysen L. et al. Lifestyle and pain following cancer: state-of-the-art and future directions. J Clin Med 2021;11(1):195. doi: 10.3390/jcm11010195
  32. Tessler J., Bordoni B. Cardiac rehabilitation. Treasure Island (FL): StatPearls Publishing, 2022. Available at: https://www.ncbi.nlm.nih.gov/ books/NBK537196/
  33. Siembida E., Smith A.W., Potosky A.L. et al. Examination of individual and multiple comorbid conditions and health-related quality of life in older cancer survivors. Qual Life Res 2021;30(4):1119–29. doi: 10.1007/s11136-020-02713-0
  34. Geršak B., Kukec A., Steen H. et al. Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients. Zdr Varst 2021;60(4):199–209. doi: 10.2478/sjph-2021-0028
  35. Bikomeye J., BeyerA.M., Kwarteng J.L. et al. Greenspace, inflammation, cardiovascular health, and cancer: a review and conceptual framework for greenspace in cardio-oncology research. Int J Environ Res Public Health 2022;19(4):2426. doi: 10.3390/ijerph19042426

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Tsyrenov D.D., Tsyrenova E.B., Sysoev S.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.